James McNab Net Worth

The estimated Net Worth of James R Mcnab is at least $5.68 Milhão dollars as of 21 September 2018. Mr. Mcnab owns over 200,000 units of Titan Pharmaceuticals, (de) stock worth over $1,689,000 and over the last 24 years he sold TTNP stock worth over $3,989,096. In addition, he makes $0 as Independent Director at Titan Pharmaceuticals, (de).

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McNab TTNP stock SEC Form 4 insiders trading

James has made over 28 trades of the Titan Pharmaceuticals, (de) stock since 2000, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of TTNP stock worth $50,000 on 21 September 2018.

The largest trade he's ever made was exercising 397,500 units of Titan Pharmaceuticals, (de) stock on 18 March 2011 worth over $556,500. On average, James trades about 44,893 units every 124 days since 2000. As of 21 September 2018 he still owns at least 300,000 units of Titan Pharmaceuticals, (de) stock.

You can see the complete history of Mr. Mcnab stock trades at the bottom of the page.

James McNab biography

James R. McNab Jr. serves as Independent Director of the Company. Mr. Akers has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company he founded. Since 2009, Mr. McNab has served as executive chairman of FirstString Research, Inc., a privately-held biopharmaceutical company. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation, a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products. He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Based on Mr. McNab’s extensive management experience in the pharmaceutical industry, our Board believes that Mr. McNab has the appropriate set of skills to serve as a member of the Board.

How old is James McNab?

James McNab is 76, he's been the Independent Director of Titan Pharmaceuticals, (de) since 2014. There are 1 older and 6 younger executives at Titan Pharmaceuticals, (de). The oldest executive at Titan Pharmaceuticals, Inc. (de) is M. David MacFarlane, 79, who is the Independent Director.

What's James McNab's mailing address?

James's mailing address filed with the SEC is 310 BROAD STREET, , CHARLESTON, SC, 29401.

Insiders trading at Titan Pharmaceuticals, (de)

Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over $4,610,001 worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth $2,558,794 . The most active insiders traders include David E.Activist Investing ..., James R Mcnab, eMarc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of $2,815,253. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth $4,610,001.

What does Titan Pharmaceuticals, (de) do?

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Complete history of Mr. Mcnab stock trades at Curis Inc e Titan Pharmaceuticals, (de)

Titan Pharmaceuticals, (de) executives and stock owners

Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include:

• Marc Rubin,
  Executive Chairman of the Board, Chief Executive Officer
• Katherine DeVarney,
  President, Chief Operating Officer, Chief Scientific Officer, Director
• Dr. Katherine L. Beebe-DeVarney Ph.D.,
  Pres, COO & Director
• Dr. Marc Rubin M.D.,
  Exec. Chairman & Principal Exec. Officer
• Stephen Kilmer,
  Investor Relations
• James McNab,
  Independent Director
• M. David MacFarlane,
  Independent Director
• Joseph Akers,
  Independent Director
• Scott Smith,
  Independent Director
• Joe Schrei,
  Exec. Director of Commercial Operations
• Jennifer Kiernan,
  Exec. Assistant to CEO & Investor Communications Coordinator
• Mike Fritz,
  National Sales Director
• Brian E. Crowley,
  VP of Fin.
• Dane Hallberg,
  See Remarks
• Eurelio M Cavalier,
  Director
• Sunil Bhonsle,
  President and CEO
• Choon Hau Choong,
  10% owner
• Rajinder Kumar,
  Director
• Matthew Charles Mc Murdo,
  Director
• David Natan,
  Director
• Peter Louis Chasey,
  Director
• Federico Seghi Recli,
  Director
• Avraham Ben Tzvi,
  Director
• David E. Lazar,
  Chief Executive Officer
• Eric Howard Greenberg,
  Director
• Katherine Beebe,
  President and COO
• David E.Activist Investing ...,
  Chief Executive Officer